Tranexamic Acid in Adherent Placenta (TAP)

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Placenta Accreta

In brief

The objective of this study is to investigate the effect of tranexamic acid (TXA) administration on the outcome of cesarean-hysterectomy in women with suspected Morbidly Adherent Placenta (MAP; placenta accreta, increta, percreta).

Key facts

Study ID

NCT02329756

Run by

Baylor College of Medicine

People needed

0

Starts

2018-12-01

Expected to finish

2021-12-01

Last updated by the study team

2018-08-23

Who can join

Age: 18 and older, up to 64. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Ultrasound and/or MRI diagnosed MAPL pregnancy scheduled to have a cesarean hysterectomy
• The responsible clinician is substantially uncertain as to whether or not to use TXA
• Consent has been given according to approved procedures

You may not qualify if…

• Women for whom the responsible clinician considers there is a clear indication for TXA should not be randomized
• Prior known thromboembolic event during pregnancy
• Known contraindication to TXA (prior adverse reaction)
• Patient unable to give adequate consent due to emergent cesarean hysterectomy
• Bleeding prior to incision
• Prior known thromboembolic event
• Women with a history of any acute venous or arterial thrombosis including retinal artery/retinal vein occlusion, cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism
• History of decreased renal function, renal cortical disease, or significant renal tract disease.

Where it is running

• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.